J.P. Morgan Day 4: Setting Goals For The Year Ahead
Updates from Viatris, Chi-Med, Novo Nordisk, Sangamo, Intercept, ImmunoGen
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.
You may also be interested in...
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.
Analysis of cardiovascular studies show GLP-1 drugs are associated with a 53% reduced risk of developing Alzheimer’s disease.
With a goal of reducing its cost base by at least $1bn by 2024, Viatris has delivered plans to significantly restructure its global manufacturing network. Up to 20% of Viatris’ 45,000-strong workforce could be impacted by the initiative which will see the firm close, divest or downsize 15 of its manufacturing plants around the globe.